Skip to main content
. 2009 Apr 21;100(8):1460–1467. doi: 10.1111/j.1349-7006.2009.01194.x

Figure 5.

Figure 5

Caspase activation is not required for cell death by cotreatment with bafilomycin A1 (BMA) and taxol (TXL). (a) Human small cell lung carcinoma Ms‐1 cell lines transfected with vector control (Ms‐1/neo) or Bcl‐xL (Ms‐1/Bcl‐xL) were treated with BMA (3 nM) and/or TXL (30 ng/mL) for 18 h. Cytochrome c in the cytosolic fraction and Poly(ADP‐ribose) polymerase (PARP) in the whole lysate were immunoblotted with each antibody. (b) Left, Ms‐1/neo and Ms‐1/Bcl‐xL were treated with BMA (3 nM) and/or TXL (30 ng/mL) in the presence or absence of z‐VAD‐fmk (100 µM) for 48 h; right, Ms‐1/neo and Ms‐1/Bcl‐xL were treated with BMA (3 nM) and/or inostamycin (INM) (0.1 µg/mL) in the presence or absence of z‐VAD‐fmk (100 µM) for 48 h. Cell viability was assessed by trypan blue dye exclusion assay. Values are the means of three samples; bars, SD.